

Review of: "mRNA: vaccine or gene therapy? Regulatory issues."

Federico Perche¹

¹ Centre de Biophysique Moléculaire

Potential competing interests: No potential competing interests to declare.

The paper is well written and is an important point of view on mRNA therapeutics.

Authors follow the classification of mRNA as a prodrug and present limitations associated. More details on the types of RNA therapeutics could have been presented, for example on self-replicative RNAs, on circular RNA. In my opinion, a timeline of positions should be added.